Research programme: Zika virus vaccine - Acuitas Therapeutics/University of Pennsylvania
Alternative Names: Pre-membrane and envelope glycoprotein mRNA-LNP; prM-E glycoprotein mRNA-LNP; Zika virus mRNA-LNP; Zika virus vaccine - Acuitas Therapeutics/University of Pennsylvania; ZIKV mRNA-LNPLatest Information Update: 28 Nov 2020
Price :
$50 *
At a glance
- Originator Acuitas Therapeutics
- Developer Acuitas Therapeutics; University of Pennsylvania
- Class RNA vaccines; Zika virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Zika virus infection
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for preclinical development in Zika-virus-infection(Prevention) in Canada (Intradermal)
- 28 Nov 2020 No recent reports of development identified for preclinical development in Zika-virus-infection(Prevention) in USA (Intradermal)
- 16 Mar 2018 Arbutus has issued and pending patents for LNP delivery technology in countries worldwide